An old Vertex drug gets new life as an Alzheimer's treatment, but human studies still far off
If you give a mouse a targeted enzyme inhibitor, will its cognitive decline slow down?
That’s what researchers from McGill University and the Lady Davis Institute in Montreal are asking, and the answer could be yes. Led by Andréa LeBlanc, the team demonstrated a link between an old Vertex drug, VX-765, and delayed cognitive impairment prior to the onset of Alzheimer’s symptoms and aging in mice. The results of the study were published in a paper in Nature Communications early Friday morning.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 102,000+ biopharma pros reading Endpoints daily — and it's free.